In clinical medicine, the "gold standard" for diagnosis often presents a paradox: the very procedure required to confirm a disease can harm the patient. Histopathologic biopsies—the physical extraction of tissue—carry inherent risks including internal hemorrhage, infection, and "needle track seeding," where malignant cells are inadvertently spread along the biopsy path (Tianqiang Song; Ji Wu et al.). Furthermore, the invasiveness of these procedures makes them unsuitable for frequent monitoring, leaving clinicians blind to how a disease progresses or responds to treatment in real-time (Ran Chen et al.).
To resolve this, researchers are developing "virtual biopsies"—non-invasive frameworks that decode high-dimensional data from medical imaging and biofluids to achieve diagnostic certainty without physical intervention.
Decoding the Hidden Language of Images
The core intuition behind virtual biopsies is that standard medical scans contain far more information than the human eye can perceive. While a radiologist looks for structural abnormalities, radiomics and deep learning algorithms extract thousands of quantitative features—textures, shapes, and intensity distributions—that correlate with microscopic tumor biology.
For example, Yaju Li et al. demonstrated that combining clinical observations with radiomic features from CT scans allows for the non-invasive differentiation of lung cancer subtypes, which typically requires a risky needle biopsy. Similarly, Yeting Wang et al. used radiomics to predict the expression of Ki-67, a protein marker for tumor aggressiveness, effectively turning a preoperative CT scan into a prognostic tool.
This "digital eye" extends to specialized imaging modalities:
- Contrast-Enhanced Ultrasound (CEUS): By tracking microbubble flow, Hejia Zhang et al. identified critical markers of kidney disease activity in children, bypassing the need for repeated renal biopsies.
- Magnetic Resonance Elastography (MRE): Zongtai Li showed that measuring tissue "stiffness" non-invasively can distinguish between normal liver tissue and aggressive carcinomas.
- Spectral CT: Jinyan Wei et al. utilized iodine distribution maps to grade renal tumors, providing a "virtual biopsy" to guide surgical planning.
Molecular Proxies in Biofluids
Beyond imaging, the research direction emphasizes "liquid biopsies"—the detection of molecular signatures in blood or urine that mirror the state of internal organs. This approach treats biofluids as a systemic record of local pathology.
Yubo Jing et al. identified a five-microRNA "fingerprint" in blood serum that detects breast cancer with high accuracy, reducing the psychological and physical burden of surgical sampling. In chronic kidney disease, Zhaomin Mao et al. discovered that levels of the protein NEU1 in urine can predict permanent scarring, offering a way to monitor structural decay that traditional biopsies cannot safely do on a frequent basis.
The Power of Multimodal Fusion
The most robust non-invasive systems do not rely on a single data source. Instead, they use multimodal fusion—integrating imaging, molecular biomarkers, and clinical data through advanced AI architectures like Transformers and Bayesian Networks.
Zheyi Dong et al. developed the Trans-MUF system, which achieves near-perfect diagnostic accuracy for diabetic nephropathy by fusing non-invasive retinal images with basic clinical data. By leveraging the biological link between the eye and the kidney, the authors provide a high-accuracy alternative to invasive kidney tissue sampling. Similarly, Wei Mu et al. showed that a "Deeply Learned Score" derived from PET/CT scans could predict immunotherapy response as effectively as traditional tissue biomarkers.
By correlating macroscopic imaging features with microscopic tumor biology, these non-invasive methods allow clinicians to assess patient risk and tailor treatments before a single incision is made (Chutong He et al.). The ultimate goal of this research is a shift from reactive, invasive sampling to proactive, digital monitoring, ensuring that the path to diagnosis is as safe as the treatment itself.